US Physical Therapy financials
$86.15+0.07%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $214.1M | $198.3M | $202.7M | $197.1M | $197.3M | $183.8M | $180.4M | $168.0M | $167.2M | $155.7M | $154.8M | $150.0M |
| Gross profit | $214.1M | $198.3M | $671.4M | $36.9M | $197.3M | $183.8M | $580.0M | $29.1M | $167.2M | $155.7M | $154.8M | $150.0M |
| Gross margin | 100.0% | 100.0% | 331.2% | 18.7% | 100.0% | 100.0% | 321.4% | 17.3% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $21.9M | $12.5M | $16.8M | $25.3M | $24.9M | $19.6M | $19.7M | $12.8M | $15.6M | $14.3M | -$880.0K | $15.9M |
| Net income | $3.8M | -$1.8M | -$6.5M | $7.2M | $8.8M | $12.1M | $7.9M | $5.8M | $7.0M | $7.0M | -$5.7M | $7.6M |
| Net margin | 1.8% | −0.9% | −3.2% | 3.7% | 4.5% | 6.6% | 4.4% | 3.5% | 4.2% | 4.5% | −3.7% | 5.1% |
| Diluted EPS | $0.25 | $-0.12 | $-0.43 | $0.48 | $0.58 | $0.80 | $0.52 | $0.39 | $0.47 | $0.46 | $-0.38 | $0.51 |
| EBITDA | $27.9M | $18.5M | $21.4M | $31.2M | $31.0M | $25.5M | $27.8M | $17.2M | $20.1M | $18.4M | $16.5M | $19.9M |
| Operating cash flow | $34.4M | $3.8M | $24.9M | $19.9M | $34.9M | -$4.7M | $19.4M | $22.1M | $29.0M | $4.4M | $26.8M | $16.4M |
| Free cash flow | $29.0M | -$1.6M | $21.0M | $15.6M | $31.6M | -$7.3M | $16.9M | $19.6M | $26.7M | $2.6M | $24.6M | $13.8M |
| Diluted shares | 15.1M | 15.2M | 15.2M | 15.2M | 15.2M | 15.1M | 15.1M | 15.1M | 15.1M | 15.0M | 15.0M | 15.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.9M | $28.4M | $35.6M | $31.1M | $34.1M | $39.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $220.0M | $204.8M | $162.5M | $160.3M | $160.1M | $166.5M |
| Total assets | $1.25B | $1.24B | $1.20B | $1.20B | $1.18B | $1.18B |
| Total liabilities | $482.2M | $459.2M | $433.8M | $413.8M | $414.0M | $420.7M |
| Shareholders' equity | $449.2M | $469.4M | $476.9M | $504.8M | $502.3M | $499.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology